240 related articles for article (PubMed ID: 36420171)
1. Pathophysiology and therapeutic advances in myeloma bone disease.
Zhang F; Zhuang J
Chronic Dis Transl Med; 2022 Dec; 8(4):264-270. PubMed ID: 36420171
[TBL] [Abstract][Full Text] [Related]
2. Biology and treatment of myeloma related bone disease.
Terpos E; Christoulas D; Gavriatopoulou M
Metabolism; 2018 Mar; 80():80-90. PubMed ID: 29175022
[TBL] [Abstract][Full Text] [Related]
3. Myeloma bone disease: pathogenesis, current treatments and future targets.
Walker RE; Lawson MA; Buckle CH; Snowden JA; Chantry AD
Br Med Bull; 2014 Sep; 111(1):117-38. PubMed ID: 25190762
[TBL] [Abstract][Full Text] [Related]
4. The role of bone-modifying agents in myeloma bone disease.
Lu H; Pundole X; Lee HC
JBMR Plus; 2021 Aug; 5(8):e10518. PubMed ID: 34368608
[TBL] [Abstract][Full Text] [Related]
5. Pathogenesis and Treatment of Myeloma-Related Bone Disease.
Gau YC; Yeh TJ; Hsu CM; Hsiao SY; Hsiao HH
Int J Mol Sci; 2022 Mar; 23(6):. PubMed ID: 35328533
[TBL] [Abstract][Full Text] [Related]
6. Bone disease in multiple myeloma: pathophysiology and management.
Hameed A; Brady JJ; Dowling P; Clynes M; O'Gorman P
Cancer Growth Metastasis; 2014; 7():33-42. PubMed ID: 25187738
[TBL] [Abstract][Full Text] [Related]
7. Monoclonal antibodies against RANKL and sclerostin for myeloma-related bone disease: can they change the standard of care?
Kleber M; Ntanasis-Stathopoulos I; Dimopoulos MA; Terpos E
Expert Rev Hematol; 2019 Aug; 12(8):651-663. PubMed ID: 31268745
[No Abstract] [Full Text] [Related]
8. Management of Myeloma Bone Lesions.
Du JS; Yen CH; Hsu CM; Hsiao HH
Int J Mol Sci; 2021 Mar; 22(7):. PubMed ID: 33806209
[TBL] [Abstract][Full Text] [Related]
9. Experience with denosumab (XGEVA®) for prevention of skeletal-related events in the 10 years after approval.
Cadieux B; Coleman R; Jafarinasabian P; Lipton A; Orlowski RZ; Saad F; Scagliotti GV; Shimizu K; Stopeck A
J Bone Oncol; 2022 Apr; 33():100416. PubMed ID: 35242510
[TBL] [Abstract][Full Text] [Related]
10. Myeloma Bone Disease: Update on Pathogenesis and Novel Treatment Strategies.
Vallet S; Filzmoser JM; Pecherstorfer M; Podar K
Pharmaceutics; 2018 Oct; 10(4):. PubMed ID: 30355994
[TBL] [Abstract][Full Text] [Related]
11. [Receptor Activator of Nuclear Factor κB Ligand-Receptor Activator of Nuclear Factor κB Signaling Pathway in Myeloma Bone Disease].
Feng Y; Tang WJ; Zou ZQ; Cui J; Zhang L; Niu T
Zhongguo Yi Xue Ke Xue Yuan Xue Bao; 2022 Aug; 44(4):686-692. PubMed ID: 36065703
[TBL] [Abstract][Full Text] [Related]
12. Mechanisms of bone destruction in multiple myeloma.
Terpos E; Christoulas D; Gavriatopoulou M; Dimopoulos MA
Eur J Cancer Care (Engl); 2017 Nov; 26(6):. PubMed ID: 28940410
[TBL] [Abstract][Full Text] [Related]
13. Prevention Of Skeletal Related Events In Multiple Myeloma: Focus On The RANK-L Pathway In The Treatment Of Multiple Myeloma.
Parrondo RD; Sher T
Onco Targets Ther; 2019; 12():8467-8478. PubMed ID: 31686861
[TBL] [Abstract][Full Text] [Related]
14. RANK ligand and osteoprotegerin in myeloma bone disease.
Sezer O; Heider U; Zavrski I; Kühne CA; Hofbauer LC
Blood; 2003 Mar; 101(6):2094-8. PubMed ID: 12424190
[TBL] [Abstract][Full Text] [Related]
15. The high rate of bone resorption in multiple myeloma is due to RANK (receptor activator of nuclear factor-kappaB) and RANK Ligand expression.
Roux S; Mariette X
Leuk Lymphoma; 2004 Jun; 45(6):1111-8. PubMed ID: 15359989
[TBL] [Abstract][Full Text] [Related]
16. Myeloma bone disease: pathophysiology and management.
Terpos E; Dimopoulos MA
Ann Oncol; 2005 Aug; 16(8):1223-31. PubMed ID: 15928069
[TBL] [Abstract][Full Text] [Related]
17. Management of bone disease in multiple myeloma.
Terpos E; Berenson J; Raje N; Roodman GD
Expert Rev Hematol; 2014 Feb; 7(1):113-25. PubMed ID: 24433088
[TBL] [Abstract][Full Text] [Related]
18. Denosumab versus zoledronic acid in bone disease treatment of newly diagnosed multiple myeloma: an international, double-blind, double-dummy, randomised, controlled, phase 3 study.
Raje N; Terpos E; Willenbacher W; Shimizu K; García-Sanz R; Durie B; Legieć W; Krejčí M; Laribi K; Zhu L; Cheng P; Warner D; Roodman GD
Lancet Oncol; 2018 Mar; 19(3):370-381. PubMed ID: 29429912
[TBL] [Abstract][Full Text] [Related]
19. The role of sclerostin/dickkopf-1 and receptor activator of nuclear factor kB ligand/osteoprotegerin signalling pathways in the development of osteoporosis in patients with haemophilia A and B: A cross-sectional study.
Anagnostis P; Vakalopoulou S; Christoulas D; Paschou SA; Papatheodorou A; Garipidou V; Kokkoris P; Terpos E
Haemophilia; 2018 Mar; 24(2):316-322. PubMed ID: 29194852
[TBL] [Abstract][Full Text] [Related]
20. Metastatic bone disease: Pathogenesis and therapeutic options: Up-date on bone metastasis management.
D'Oronzo S; Coleman R; Brown J; Silvestris F
J Bone Oncol; 2019 Apr; 15():004-4. PubMed ID: 30937279
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
